Emergence client, Microsintesis, gets US nod of approval

January 25, 2018

Emergence client, Oakville, Ontario- and Charlottetown, PEI-based MicroSintesis Inc. has received permits to sell its dried L. acidophilus fermentation product in the states of Missouri and Nebraska under the Association of American Feed Control Officials ingredient 36.11.

Microsintesis is a life sciences company focused on creating novel products to promote and maintain animal gut health.

nuvio-bottlesTheir product, Nuvio is also listed with Canadian Food Inspection Agency as a feed ingredient.

Nuvio uses a newly discovered technology containing probiotic metabolites which promote and enhance the gut health of animals.

This effect supports the growth and health of the animals during periods of challenge and stress, particularly in situations like post weaning.

Initially discovered at the University of Guelph, the development of the product has been a collaborative effort between MicroSintesis and the university, and has been independently validated in clinical research studies as well as a veterinary monitored commercial field trials.


Hannah McIver

“MicroSintesis continues to push at the forefront of probiotic research to deliver real alternatives to antibiotic use in livestock,” MicroSintesis CEO, Hannah McIver, told us.

“We are delighted to have begun the registration process in the USA as we strive to deliver new health solutions to livestock producers, globally ”

Nuvio is administered in the drinking water for the first 14 days post-weaning. For more information visit: http://microsintesis.com/nuvio/


About MicroSintesis

Founded in 2011, MicroSintesis is a Canadian life sciences company focused on creating novel animal health products. By harnessing the natural defense mechanisms of probiotics, MicroSintesis is on the forefront of new animal health products. MicroSintesis has developed a unique manufacturing process, which is to the highest standard of quality assurance, to deliver products that are simple, natural, well-defined, and supported by clinical assays, for deliverable success.